SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
People And Robots Handshake Modern Human And Artificial Intelligence Futuristic Mechanism Technology Vector Illustration
Artificial intelligence
In latest AI Play, Sanofi Bets $630M+ for Formation Bio’s JAK/SYK Blocker
The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi will explore additional indications for gusacitinib in a Phase I study.
June 24, 2025
 · 
2 min read
 · 
Tristan Manalac
Novo Nordisk and Eli Lilly buildings
Weight loss
Lilly’s Antibody Protects Patients From Losing Muscle While Taking Novo’s Wegovy
Eli Lilly’s bimagrumab led to weight loss that was due almost entirely to fat reduction when combined with semaglutide, marketed by rival Novo Nordisk as Wegovy. BMO Capital Markets called the data “impressive” while raising concerns about the antibody’s safety profile.
June 24, 2025
 · 
2 min read
 · 
Tristan Manalac
Opinion
Washington’s Policy Shifts Are Driving Capital Away From Life-Saving Research
Drug pricing, budget cuts, tariffs and other shifts under the Trump administration undermine the biopharma and healthcare ecosystem.
June 24, 2025
 · 
4 min read
 · 
John Stanford
Pictured: (From L) Joe Ross, Camille Bedrosian, Emil Kakkis and Heather McKenzie
Rare diseases
FDA Conditional Pathway Not Necessary, Rare Disease Experts Say, While Applauding Intent
Speaking at BIO2025, rare disease leaders from Ultragenyx, Amylyx and Yale questioned the need for the new regulatory pathway proposed by FDA Commissioner Marty Makary. They acknowledged, however, that creative thinking is required to enable more treatments for patients with ultrarare diseases.
June 24, 2025
 · 
3 min read
 · 
Heather McKenzie
A group of people sitting before microphones at a table on a stage
Government
Acting CDER Head Becomes Latest in String of FDA Leaders to Leave Agency
Jacqueline Corrigan-Curay, who stepped into the role as the agency’s top drug regulator in January, is departing in July, according to an email sent to agency staff.
June 23, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Isometric Breaking the Wall. An alternative Solution to the Problem. Businessman Solved Problem, New Solution, Success and Leadership. Breakthrough. Business concept.
Weight Loss
Lilly Takes Victory Lap on Oral Weight Loss Drug as Analysts Spot Safety Crack
While Eli Lilly brushed off concerns about gastrointestinal side effects for oral weight loss candidate orforglipron, analysts from William Blair worried that adverse events are not tapering off as expected.
June 23, 2025
 · 
5 min read
 · 
Annalee Armstrong
leader crossed forbidden line, leadership vector concept, finish line and winner
Cancer
Exelixis Beats Bayer in Colorectal Cancer as Zanzalintinib Delivers ‘First Pivotal Success’
In combination with Roche’s PD-L1 blocker Tecentriq, zanzalintinib bested Bayer’s Stivarga. Exelixis is positioning the drug candidate as a successor to cabozantinib, which is set to lose patent exclusivity in 2030.
June 23, 2025
 · 
2 min read
 · 
Tristan Manalac
Corporate headquarters of Novo Nordisk in Denmark
Obesity
Novo Leans on CagriSema’s Safety as Amycretin Moves Forward to Phase III
After consistently failing to meet investor expectations, Novo Nordisk touted a safety profile for CagriSema in line with the GLP1-RA class, while reporting mid-stage data for its GLP1- and amylin-targeting drug amycretin that raised dosing questions.
June 23, 2025
 · 
2 min read
 · 
Tristan Manalac
Man walking on a boardwalk in the fog
Depression
Compass Plots Path to FDA With ‘Meaningful’ Phase III Data for Psilocybin Drug in Depression
Although the company withheld detailed findings from the study of treatment-resistant depression, analysts at Stifel called COMP360’s efficacy “more than good enough” for registrational purposes.
June 23, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS